Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

Model scores of the 29,894 trials active now.

Model score 43% for any early termination, 28% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustcancerchemotherapycelltreating
  Phrases that lowered it: tractdiseasesclinical trialrnasafety of
• Sponsor's past termination rate: 26.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 95.7% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 22.7% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Sponsor's past trials: 52 (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 4531 (lowers risk) · Drug's FDA history
• Keywords listed: 3 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer NCT02412670 · started 2015 · scored riskier than 94% of active trials completed
• Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer NCT02560038 · started 2015 · scored riskier than 99% of active trials terminated
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer NCT03288545 · started 2017 · scored riskier than 88% of active trials terminated
• Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer NCT00749892 · started 2008 · scored riskier than 96% of active trials completed
• Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study NCT04398368 · started 2020 · scored riskier than 63% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.